Literature DB >> 12079297

Long-term survival and patterns of care in women with ovarian tumors of low malignant potential.

Cornelia Liu Trimble1, Carol Kosary, Edward L Trimble.   

Abstract

OBJECTIVES: The objectives of this study were to ascertain long-term survival and patterns of care among women diagnosed with ovarian tumors of low malignant potential (LMP) in a population-based data set.
METHODS: Using the NCI's Surveillance, Epidemiology, and End Results (SEER) database, we identified 2818 women diagnosed with ovarian tumors of low malignant potential between 1988 and 1997.
RESULTS: By FIGO stage, 10-year relative survival was as follows: stage I, 99%; stage II, 98%; stage III, 96%; and stage IV 77%. One-quarter of women with stage I disease underwent partial or unilateral oophorectomy only, while women with more advanced disease commonly underwent omentectomy, unilateral or bilateral oophorectomy, and hysterectomy. Adjuvant chemotherapy was given to about 30% of women with stage III and IV disease. Radiation therapy was rarely used. We observed no significant changes in primary surgery or adjuvant treatment over time.
CONCLUSIONS: The diagnosis of an ovarian tumor of LMP conveys a relatively benign prognosis. Conservative surgery should be considered in younger women with early-stage disease. There are insufficient data to support a role for adjuvant chemotherapy for women with advanced disease. (c) 2002 Elsevier Science (USA).

Entities:  

Mesh:

Year:  2002        PMID: 12079297     DOI: 10.1006/gyno.2002.6711

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  24 in total

1.  Micropapillary pattern in newly diagnosed borderline tumors of the ovary: what's in a name?

Authors:  Mario M Leitao
Journal:  Oncologist       Date:  2011-01-27

2.  Management of Borderline Ovarian Tumors-Still a Gray Zone.

Authors:  Nidhi Nayyar; Prerna Lakhwani; Ashish Goel; Pankaj Kr Pande; Kapil Kumar
Journal:  Indian J Surg Oncol       Date:  2017-08-25

3.  Accuracy of Intraoperative Frozen Section Diagnosis of Borderline Ovarian Tumors by Hospital Type.

Authors:  Jaimin S Shah; Michael Mackelvie; David M Gershenson; Preetha Ramalingam; Marylee M Kott; Jubilee Brown; Polly Gauthier; Elizabeth Nugent; Lois M Ramondetta; Michael Frumovitz
Journal:  J Minim Invasive Gynecol       Date:  2018-04-19       Impact factor: 4.137

4.  Adnexal masses and malignancies of importance to the colorectal surgeon.

Authors:  Richard C Kline; Lisa B Bazzett-Matabele
Journal:  Clin Colon Rectal Surg       Date:  2010-06

5.  Risk factors for recurrence of ovarian borderline tumors.

Authors:  K K Shih; Q Zhou; J Huh; J C Morgan; A Iasonos; C Aghajanian; D S Chi; R R Barakat; N R Abu-Rustum
Journal:  Gynecol Oncol       Date:  2010-12-10       Impact factor: 5.482

Review 6.  Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.

Authors:  Murray Joseph Casey; Chhanda Bewtra
Journal:  Fam Cancer       Date:  2004       Impact factor: 2.375

7.  Major Clinical Impact of Platinum-Based Chemotherapy in a Patient with a Borderline Ovarian Cancer.

Authors:  Jian Chen; Maurie Markman
Journal:  Case Rep Oncol       Date:  2009-09-22

8.  [Specialized histopathological second opinion of advanced ovarian cancer. Experiences with collectives from prospective randomized phase III studies].

Authors:  S Kommoss; J Pfisterer; A du Bois; D Schmidt; F Kommoss
Journal:  Pathologe       Date:  2014-07       Impact factor: 1.011

9.  Gross genomic alterations differ between serous borderline tumors and serous adenocarcinomas--an image cytometric DNA ploidy analysis of 307 cases with histogenetic implications.

Authors:  Manohar Pradhan; Ben Davidson; Claes Göran Tropé; Håvard Emil Danielsen; Vera Maria Abeler; Björn Risberg
Journal:  Virchows Arch       Date:  2009-05-08       Impact factor: 4.064

10.  Diffusion-weighted MR imaging for differentiating borderline from malignant epithelial tumours of the ovary: pathological correlation.

Authors:  Shu Hui Zhao; Jin Wei Qiang; Guo Fu Zhang; Feng Hua Ma; Song Qi Cai; Hai Ming Li; Li Wang
Journal:  Eur Radiol       Date:  2014-05-29       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.